1-3 of 3
Kaiming Sun
Close
Sort by
Journal Articles

The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL

Kaiming Sun, PhD, Ruzanna Atoyan, MD, Mylissa A Borek, MS, Steven Dellarocca, MS, Garrett Rhyasen, PhD, Ali Fattaey, PhD, David P Tuck, MD
Journal: Blood
Blood (2016) 128 (22): 4184.
https://doi.org/10.1182/blood.V128.22.4184.4184
Published: 2016
Journal Articles

Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma

Anas Younes, MD, Jesus G. Berdeja, MD, Manish R. Patel, MD, Kevin R. Kelly, MD PhD, Ian W. Flinn, MD PhD, John F Gerecitano, MD PhD, Sattva S. Neelapu, MD, Amanda R. Copeland, RN, MSN, CNS, Amy Akins, RN, BSN, CCRC, Myles Clancy, Anna Ma, MS, Kaiming Sun, PhD, Ze Tian, PhD, Jing Wang, PhD, Jaye Viner, MD MPH, Yasuhiro Oki, MD
Journal: Blood
Blood (2015) 126 (23): 257.
https://doi.org/10.1182/blood.V126.23.257.257
Published: 2015
Journal Articles

Stapled Peptides: Leveraging the BH3 α-Helix to Create a New Class of Drugs to Treat Hematological Malignancies

Rosana Kapeller, Jiawen Han, Kaiming Sun, Pranoti Gangurde, Nori Kawahata, Matt Iadanza, Vincent Guerlevais, Jim Horstick, Justin Noehre, Allen Annis, Larry Licklider, Huw M. Nash, Andrew Kung, Tomi K. Sawyer
Journal: Blood
Blood (2008) 112 (11): 2929.
https://doi.org/10.1182/blood.V112.11.2929.2929
Published: 2008